Cargando…
The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer
Metastatic prostate cancer is treated with androgen ablation therapy but progress to castrate resistant prostate cancer (CRPC). This study aimed to investigate the role of CUX1 in CRPC using clinical samples and in vitro models. CUX1 expression was increased in androgen-independent cells compared to...
Autores principales: | Dorris, Emma R., O’Neill, Amanda, Treacy, Ann, Klocker, Helmut, Teltsh, Omri, Kay, Elaine, Watson, R. William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061738/ https://www.ncbi.nlm.nih.gov/pubmed/32180898 http://dx.doi.org/10.18632/oncotarget.27494 |
Ejemplares similares
-
MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer
por: Dorris, Emma, et al.
Publicado: (2017) -
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015) -
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013) -
KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021) -
The Transcription Factor Cux1 Regulates Dendritic Morphology of Cortical Pyramidal Neurons
por: Li, Ning, et al.
Publicado: (2010)